Immune checkpoint inhibitor drugs have a high target affinity and specificity in comparison with its counterparts. Additionally, rising approval rating of these drugs and declined cost are major factors propelling product demand globally. Unlike most of the approved therapies, which have severe side effects during cancer treatments, immune checkpoint inhibitor drugs found to be a better alternative.
Consequently, the market has witnessed growing popularity for immune checkpoint inhibitor among healthcare professional in the last couple of years. Immune checkpoint inhibitors drugs are highly tar specific and work directly on the target, thus making them highly effective than conventional treatments. North America currently hold major market share, owing to the rising partnerships and collaborations among private players for developing new drugs.
Major players dominating the global market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, and ImmunOs Therapeutics AG.
The report titled “Immune Checkpoint Inhibitors Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032”, wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global immune checkpoint inhibitors market.
Furthermore, the report would reflect on the key developments, global & regional sales network, business strategies, security & exchange overview, research & development activities, production facilities, product portfolio, employee strength, and key executive, for all the players considered under the scope of study. For instance, AstraZeneca Plc. operates through five segments namely Oncology, Cardiovascular, Renal and Metabolism, Respiratory, and Others. Moreover, the company offers Immune Checkpoint Inhibitors under the Oncology business segment which generated revenue of US$ 6028 Mn in 2018.
The immune checkpoint inhibitors market study takes into consideration market segmentation based on type, application, distribution channel, and geography. Based on type, the market is segmented into CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. Based on applications, the global immune checkpoint inhibitor market is segmented into lung cancer, melanoma, urothelial carcinoma, squamous cell carcinoma, blood cancer, and other cancers. On the basis of distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on geography, the market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
Additionally, the study provides in-depth analysis of individual company considered under the scope of study with a focus on all operating business segment, and would identify the segment of the company focusing on immune checkpoint inhibitors market. Further, market share of company in the global market would also be calculated. For instance, Bristol-Myers Squibb’s $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert. The report study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the immune checkpoint inhibitors companies.
Furthermore, the global immune checkpoint inhibitors market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the immune checkpoint inhibitors business segment of the company.
Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global immune checkpoint inhibitors market. For instance, AstraZeneca Plc reported revenues of US$ 22.09 Billion in 2018 and the segment and geographic analysis of the company indicates that cardiovascular, renal and metabolism is the dominating revenue segment of the company, with the North America being the major revenue generating region.
Market Segmentation:
By Type
- CTLA-4 inhibitor
- PD-1 inhibitor
- PD-L1 inhibitor
By Application
- lung cancer
- melanoma
- urothelial carcinoma
- squamous cell carcinoma
- blood cancer
- other cancers
By Distribution channel
- hospital pharmacies
- retail pharmacies
- online pharmacies
By Regions
- North America
- Europe
- Asia-Pacific
- South America
- Middle East and Africa
